Fujifilm Wako Introduces Pyrostar ES-F Line to U.S.

By Contract Pharma Staff | 06.26.20

A line of reagents engineered to detect the presence of bacterial endotoxins.

Fujifilm Wako Chemicals U.S.A. Corporation, a wholly owned subsidiary of Fujifilm Wako Pure Chemical Corporation of Japan, has announced the U.S. introduction of the Pyrostar ES-F line of limulus amebocyte lysate (LAL) reagents, which are engineered to detect the presence of bacterial endotoxins. 
 
The detection of endotoxins is required in a number of industries, including medical device and vaccine manufacturing, to minimize bacterial contamination in final product. As vaccine manufacturing is expected to increase due to COVID-191, bacterial endotoxin testing will be an important quality assurance measure to ensure patient safety. 
 
Pyrostar ES-F is designed for the specific determination of gram-negative bacterial endotoxins, while also remaining unreactive to (1,3)-ß-D-glucan. Additionally, Pyrostar ES-F  is dual-purpose and can perform as either a quantitative turbidimetric (KTA) or qualitative gel- clot test assay. Available in both a single-test or multi-test configuration, the Pyrostar ES-F line of reagents fits a wide range of quality control needs in environments where medical devices and vaccines are manufactured. 
 
“As the demand grows for vaccines especially in the wake of COVID-19, Fujifilm Wako understands the need for accurate and dependable bacterial endotoxin testing to ensure vaccines are not  contaminated with harmful bacteria,” said Lisa Komski, general manager LAL sales, Fujifilm Wako Chemicals U.S.A. Corporation. “Mitigating risk to patients and complying with regulatory standards is vital. Endotoxin testing helps pharmaceutical companies avoid releasing defective products to the market. More importantly, it protects vulnerable patients.” 
 
Fujifilm Wako will distribute the Pyrostar ES-F reagents under their Limulus Amebocyte Lysate (LAL) Division in the U.S.
 
Reference
1 According to Regulatory Affairs Professional Society (RAPS), 32 COVID-19 vaccine candidates currently in clinical trials (as of June 18)